UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

September 24, 2015

Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.

September 22, 2015

Jeanine Stiles, chief administrative officer, associate director for administration, UC Davis Comprehensive Cancer Center, discusses the importance of supportive care for patients with cancer.

August 03, 2015

Clinical trial designs are undergoing a dramatic transformation geared toward the discovery and validation of new predictive biomarkers.

August 01, 2015

A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.

November 13, 2014

The rise of oral anticancer agents is revolutionizing cancer treatment for both patients and cancer care providers. Patients can take their medications in the comfort of their own homes without the need for needles, long stints in infusion chairs or intensive nursing oversight.

August 11, 2014

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

August 07, 2014

Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray.

July 30, 2014

For many years, we in the medical and research communities have tried to use proteins and DNA fragments as disease markers to find cancer early.

February 18, 2014

Using blood samples collected from the Andean villagers, the laboratory at the UC Davis Genome Center uses a variety of high-throughput genetic analysis techniques to screen for genetic differences.

December 16, 2013

The UC Davis Comprehensive Cancer Center and the National Cancer Institute (NCI)-funded National Center for Reducing Asian American Cancer Health Disparities are working to address these disparities through programs to boost participation in clinical trials, collect biospecimens, and conduct blood genomics research.

September 18, 2013

The section of General Thoracic Surgery at UC Davis is offering Robotic Thoracic Surgery to further enhance our top regional minimally invasive thoracic surgery program.

September 04, 2013

Prostate cancer has a propensity to metastasize to bone. High turnover ultimately results in a net loss of bone tissue; prostate cancer treatment contributes to the loss of bone integrity, as androgen- deprivation therapy often causes abnormally low bone density

August 28, 2013

UC Davis CLSP is a multidisciplinary program for comprehensive lung cancer screening.

August 22, 2013

Brought to you by the UC Davis Section of General Thoracic Surgery: PulmaCalc PPO is a predicted post-operative pulmonary function calculator

July 26, 2013

David R. Gandara, MD, from the UC Davis Cancer Center, discusses the 2013 recipient of the Giants in Cancer Care award in the field of thoracic oncology: Thomas J. Lynch, Jr., MD.

July 17, 2013

Primo Lara, MD, and his son, Matthew Stephen Lara, discuss an analysis of predictors of survival for younger patients with non-small cell lung cancer.

May 29, 2013

Arta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.

February 18, 2013

For patients battling a disease recurrence, results from tests in mice can translate to novel treatment approaches for individual cancer patients.

January 17, 2013

Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.

January 12, 2013

The 7th edition TNM staging system for NSCLC is an exciting accomplishment, and will help the clinician to better understand the outcomes of lung cancer and offers an exciting advance to our specialty.